Clinical Trial Update: Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201 [Phase 2]

View source ↗

Summary

An update on the long-term safety of QGE031 in allergic asthma patients who completed a prior Phase 2 study, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• QGE031

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 2 | Status: TERMINATED | Results posted: 2017-04-25